← Back to Search

Other

NRCT-101SR + NRCT-202XR for ADHD

Phase 2
Recruiting
Research Sponsored by Neurocentria, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Male or female, 13-17 years of age at screening.
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing a new treatment for ADHD that combines NRCT-101 with NRCT-202."

Who is the study for?
This trial is for boys and girls aged 13-17 with a confirmed diagnosis of ADHD, who have been on ADHD medication consistently. They must be experiencing side effects from their current treatment, speak English fluently, and both the participant and their guardian must consent to join.
What is being tested?
The study is testing if combining two drugs (NRCT-101SR with NRCT-202XR) is more effective for treating ADHD than using NRCT-202XR alone. Participants will be randomly assigned to either receive both drugs or just one in a double-blind setting where neither they nor the researchers know which group they're in.
What are the potential side effects?
Potential side effects are not specified but may include those commonly associated with ADHD medications such as sleep problems, decreased appetite, mood swings, increased blood pressure, and heart rate changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 13 and 17 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
CBRS-P

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Arm 1Active Control1 Intervention
NRCT-101SR and low dose NRCT-202XR
Group II: Arm 2Active Control1 Intervention
NRCT-101SR placebo and high dose NRCT-202XR
Group III: Arm 3Active Control1 Intervention
NRCT-101SR placebo and low dose NRCT-202XR

Find a Location

Who is running the clinical trial?

Neurocentria, Inc.Lead Sponsor
6 Previous Clinical Trials
482 Total Patients Enrolled
3 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
403 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Mary Miller, MSStudy DirectorNeurocentria, Inc.
~40 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top